Affordable Access

Publisher Website

Comparison of the class-1 outer membrane protein from B:15:P1.16Neisseria meningitidisstrains isolated from patients previously immunized with a serogroup B outer membrane protein vaccine in Norway

Authors
Journal
Microbial Pathogenesis
0882-4010
Publisher
Elsevier
Publication Date
Volume
17
Issue
6
Identifiers
DOI: 10.1006/mpat.1994.1087
Keywords
  • Neisseria Meningitidis
  • Poragene
  • Group B Outer Membrane Protein Vaccine
Disciplines
  • Biology
  • Medicine

Abstract

Abstract A previous report of a large, double blind, efficacy trial of an experimental Group B meningococcal outer membrane protein vaccine carried out in Norwegian Teenagers, showed a protection rate of 57%. Previous studies had demonstrated the occurrence of mutations in the class-1 outer membrane protein which alter its immunological properties. The occurrence of new mutations might compromise the efficacy of a vaccine and explain the occurrence of any vaccine failures. The porA gene, which encodes expression of the class 1 protein, was sequenced in all isolates from vaccine failures and compared to that of the vaccinating strain H44/76 (B:15:P1.7,16). The porA DNA and deduced amino acid sequences were all identical to that of the vaccinating strain except for that of one isolate which had a sequence identical to strains previously reported in Norway and England with a 'masked P1.7' epitope. The absence of new mutations in the trial was encouraging for the further development of outer membrane protein vaccines.

There are no comments yet on this publication. Be the first to share your thoughts.